Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1570

Inebilizumab

Home » Inebilizumab

Background of Inebilizumab

CD19 is a transmembrane glycoprotein specific to B-lineage cells, with expression maintained in over 95% of B-cell malignancies. Inebilizumab, is a humanized monoclonal antibody specifically developed for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are positive for aquaporin-4 (AQP4) antibodies. NMOSD is a rare autoimmune condition characterized by the immune system attacking the optic nerves and spinal cord, leading to severe neurological impairments. By binding to CD19, inebilizumab induces cell death through antibody-dependent cellular cytotoxicity, thereby reducing the production of AQP4 antibodies that contribute to nerve damage

Specifications

Catalog Number:
KB-1570
Antibody Name:
Inebilizumab
Isotype:
Human IgG1,kappa
FC Muations:
K214R/D356E/L358M/K447Del
Target:
CD19
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
  2. Efficacy and Safety of Inebilizumab, an Anti-CD19 Monoclonal Antibody, for the Treatment of Neuromyelitis Optica Spectrum Disorder: Based on the N-MOmentum Trial .